Nolan Seonaid, Dias Lima Viviane, Fairbairn Nadia, Kerr Thomas, Montaner Julio, Grebely Jason, Wood Evan
British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, Canada; Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Addiction. 2014 Dec;109(12):2053-9. doi: 10.1111/add.12682. Epub 2014 Aug 14.
To determine the relationship between methadone maintenance therapy (MMT) and hepatitis C (HCV) seroconversion among illicit drug users.
A generalized estimating equation model assuming a binomial distribution and a logit-link function was used to examine for a possible protective effect of MMT use on HCV incidence.
Data from three prospective cohort studies of illicit drug users in Vancouver, Canada between 1996 and 2012.
A total of 1004 HCV antibody-negative illicit drug users stratified by exposure to MMT.
Baseline and semi-annual HCV antibody testing and standardized interviewer-administered questionnaire soliciting self-reported data relating to drug use patterns, risk behaviors, detailed socio-demographic data and status of active participation in an MMT program.
One hundred and eighty-four HCV seroconversions were observed for an HCV incidence density of 6.32 [95% confidence interval (CI) = 5.44-7.31] per 100 person-years. After adjusting for potential confounders, MMT exposure was protective against HCV seroconversion [adjusted odds ratio (AOR) = 0.47; 95% CI = 0.29-0.76]. In subanalyses, a dose-response protective effect of increasing MMT exposure on HCV incidence (AOR = 0.87; 95% CI = 0.78-0.97) per increasing 6-month period exposed to MMT was observed.
Participation in methadone maintenance treatment appears to be highly protective against hepatitis C incidence among illicit drug users. There appears to be a dose-response protective effect of increasing methadone exposure on hepatitis C incidence.
确定非法药物使用者中美沙酮维持治疗(MMT)与丙型肝炎病毒(HCV)血清学转换之间的关系。
采用假定二项分布和对数链接函数的广义估计方程模型,检验MMT使用对HCV发病率的可能保护作用。
来自加拿大温哥华1996年至2012年间三项非法药物使用者前瞻性队列研究的数据。
共有1004名HCV抗体阴性的非法药物使用者,根据是否接受MMT进行分层。
基线和半年一次的HCV抗体检测,以及由标准化访员管理的问卷,收集与药物使用模式、风险行为、详细社会人口统计学数据以及积极参与MMT项目状况相关的自我报告数据。
观察到184例HCV血清学转换,HCV发病密度为每100人年6.32[95%置信区间(CI)=5.44 - 7.31]。在调整潜在混杂因素后,MMT暴露对HCV血清学转换具有保护作用[调整后的优势比(AOR)=0.47;95%CI = 0.29 - 0.76]。在亚组分析中,观察到每增加6个月MMT暴露时间,MMT暴露增加对HCV发病率有剂量反应保护作用(AOR = 0.87;95%CI = 0.78 - 0.97)。
参与美沙酮维持治疗似乎对非法药物使用者的丙型肝炎发病率具有高度保护作用。增加美沙酮暴露量对丙型肝炎发病率似乎有剂量反应保护作用。